Tags

Type your tag names separated by a space and hit enter

Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Dig Liver Dis 2006; 38(2):85-90DL

Abstract

BACKGROUND

Acid suppression is the mainstay of therapy in gastro-oesophageal reflux disease. Esomeprazole 40 mg is more effective than lansoprazole 30 mg in healing mucosal lesions in severe erosive reflux oesophagitis. However, data comparing esomeprazole with lansoprazole in patients with complications of gastro-oesophageal reflux disease, such as ulcerative reflux oesophagitis and Barrett's oesophagus, are lacking.

AIM

To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease.

METHODS

Thirty patients with complicated gastro-oesophageal reflux disease (7 with ulcerative reflux oesophagitis and 23 with Barrett's oesophagus), randomly assigned to receive 40 mg esomeprazole (n=16) or 30 mg lansoprazole (n=14) once daily, underwent oesophageal 24-h pH monitoring while on therapy. Total, upright diurnal and supine nocturnal percentage acid reflux time were assessed.

RESULTS

Esomeprazole was significantly more effective than lansoprazole in decreasing oesophageal acid exposure. Normalisation of both total and supine nocturnal percentage acid reflux time was obtained in 12 of 16 (75%) patients treated with esomeprazole but only in 4 of 14 (28%) cases treated with lansoprazole (p=0.026).

CONCLUSIONS

Normalisation of oesophageal acid exposure can be achieved in the majority of complicated gastro-oesophageal reflux disease cases with esomeprazole 40 mg once daily.

Authors+Show Affiliations

Internal Medicine and Gastroenterology Unit, New S. Agostino Hospital, Via Martignana 51, Modena 41100, Italy. m.frazzoni@ausl.mo.itNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16289976

Citation

Frazzoni, M, et al. "Intra-oesophageal Acid Suppression in Complicated Gastro-oesophageal Reflux Disease: Esomeprazole Versus Lansoprazole." Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 38, no. 2, 2006, pp. 85-90.
Frazzoni M, Manno M, De Micheli E, et al. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. Dig Liver Dis. 2006;38(2):85-90.
Frazzoni, M., Manno, M., De Micheli, E., & Savarino, V. (2006). Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 38(2), pp. 85-90.
Frazzoni M, et al. Intra-oesophageal Acid Suppression in Complicated Gastro-oesophageal Reflux Disease: Esomeprazole Versus Lansoprazole. Dig Liver Dis. 2006;38(2):85-90. PubMed PMID: 16289976.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. AU - Frazzoni,M, AU - Manno,M, AU - De Micheli,E, AU - Savarino,V, Y1 - 2005/11/10/ PY - 2005/06/26/received PY - 2005/09/15/revised PY - 2005/10/03/accepted PY - 2005/11/18/pubmed PY - 2006/6/29/medline PY - 2005/11/18/entrez SP - 85 EP - 90 JF - Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver JO - Dig Liver Dis VL - 38 IS - 2 N2 - BACKGROUND: Acid suppression is the mainstay of therapy in gastro-oesophageal reflux disease. Esomeprazole 40 mg is more effective than lansoprazole 30 mg in healing mucosal lesions in severe erosive reflux oesophagitis. However, data comparing esomeprazole with lansoprazole in patients with complications of gastro-oesophageal reflux disease, such as ulcerative reflux oesophagitis and Barrett's oesophagus, are lacking. AIM: To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease. METHODS: Thirty patients with complicated gastro-oesophageal reflux disease (7 with ulcerative reflux oesophagitis and 23 with Barrett's oesophagus), randomly assigned to receive 40 mg esomeprazole (n=16) or 30 mg lansoprazole (n=14) once daily, underwent oesophageal 24-h pH monitoring while on therapy. Total, upright diurnal and supine nocturnal percentage acid reflux time were assessed. RESULTS: Esomeprazole was significantly more effective than lansoprazole in decreasing oesophageal acid exposure. Normalisation of both total and supine nocturnal percentage acid reflux time was obtained in 12 of 16 (75%) patients treated with esomeprazole but only in 4 of 14 (28%) cases treated with lansoprazole (p=0.026). CONCLUSIONS: Normalisation of oesophageal acid exposure can be achieved in the majority of complicated gastro-oesophageal reflux disease cases with esomeprazole 40 mg once daily. SN - 1590-8658 UR - https://www.unboundmedicine.com/medline/citation/16289976/Intra_oesophageal_acid_suppression_in_complicated_gastro_oesophageal_reflux_disease:_esomeprazole_versus_lansoprazole_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1590-8658(05)00421-4 DB - PRIME DP - Unbound Medicine ER -